Allianz Asset Management
ARCT icon

Allianz Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Allianz Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-180,116
Closed -$4.39M – 2182
2024
Q2 		$4.39M Buy
+180,116
New +$5.46M 0.01% 1029
2021
Q2 		– Sell
-10,508
Closed -$434K – 2381
2021
Q1 		$434K Buy
10,508
+3,637
+53% +$217K ﹤0.01% 1942
2020
Q4 		$298K Sell
6,871
-19,894
-74% -$1.35M ﹤0.01% 1745
2020
Q3 		$1.15M Sell
26,765
-8,460
-24% -$420K ﹤0.01% 1393
2020
Q2 		$1.65M Buy
+35,225
New +$1.21M ﹤0.01% 1681

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allianz Asset Management's ARCT Position: Q3 2024 in Review

Allianz Asset Management sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 180,116 shares — an estimated $4.39M sold.

Allianz Asset Management first reported a position in ARCT in Q2 2020 and held it in 5 quarters. The position peaked at $4.39M in Q2 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Allianz Asset Management reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Allianz Asset Management sold 180,116 Arcturus Therapeutics shares in Q3 2024, an estimated $4.39M.
  • Allianz Asset Management first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 5 quarters.
  • Allianz Asset Management's Arcturus Therapeutics position peaked at $4.39M in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Allianz Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.